

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Sunghoon Kim et al.
Title: IMMUNOLOGICAL ENHANCEMENT AGENT
COMPRISING N-TERMINAL PEPTIDE OF P43 AS AN
EFFECTIVE COMPONENT
Appl. No.: 09/930,169
Filing Date: August 16, 2001
Examiner: Michael L. Borin
Art Unit: 1631

AMENDMENT TRANSMITTAL

Mail Stop NON-FEE AMENDMENT
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

RECEIVED

JUN 11 2003

TECH CENTER 1600/2900

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☒ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.
- ☐ Small Entity statement is enclosed.
- ☒ The fee required for additional claims is calculated below:

	Claims as Amended		Previously Paid For		Extra Claims Present		Rate		Additional Claims Fee
Total Claims:	3	—	20	=	0	x	\$18.00	=	\$0.00
Independents:	3	—	3	=	0	x	\$84.00	=	\$0.00
First presentation of any Multiple Dependent Claims:						+	\$280.00	=	\$0.00
CLAIMS FEE TOTAL:									\$0.00

- ☐ Applicant hereby petitions for an extension of time under 37 C.F.R. §1.136(a) for the total number of months checked below:

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$410.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the third month:	\$930.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,450.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,970.00	\$0.00
	EXTENSION FEE TOTAL:		\$0.00
<input type="checkbox"/>	Statutory Disclaimer Fee under 37 C.F.R. 1.20(d):	\$55.00	\$0.00
	CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:		\$0.00
<input checked="" type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$0.00
	TOTAL FEE:		\$0.00

☒ Response to Restriction Requirement and Preliminary Amendment is enclosed (4 pages).

☐ Please charge Deposit Account No. 19-0741 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.

☐ A check in the amount of \$0.00 is enclosed.

☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date June 9, 2003

By 

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5446
Facsimile: (202) 672-5399

Matthew E. Mulkeen
Registration No. 44,250



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9/16.T.
6/14.
Election

Applicant: Sunghoon Kim *et al.*
Title: IMMUNOLOGICAL ENHANCEMENT AGENT
COMPRISING N-TERMINAL PEPTIDE OF P43 AS
AN EFFECTIVE COMPONENT
Application No.: 09/930,169
Filing Date: August 16, 2001
Examiner: Michael L. Borin
Art Unit: 1631

RECEIVED
JUN 11 2003
TECH CENTER 1600/2900

**RESPONSE TO RESTRICTION REQUIREMENT AND
PRELIMINARY AMENDMENT**

Mail Stop Non Fee Amendment
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

The amendments presented below are in compliance with the revised amendment format permitted in the "Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office," dated February 10, 2003, and published at 1267 *OG* 106 on February 25, 2003. Thus, the provisions of 37 CFR 1.121(a), (b), (c) and (d) are waived for amendments made in this application to the claims, specification, and drawings. Accordingly, prior to examination of the present application, applicants respectfully request that the above-identified application be amended as follows:

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this document.

Remarks/Arguments begin on page 3 of this document.